Publications

New Medicine Approvals

This article is more than five years old. Some content may no longer be current.

Prescriber Update 37(3): 47
September 2016

For the period 16 April to 15 July 2016

Trade Name (Active Ingredient)	Dose Form and Strength	Therapeutic Area
Alacare (aminolevulinic acid)	Dermal patch 8 mg	Actinic keratosis lesions on the face and scalp
Daklinza (daclatasvir)	Tablet 30 mg	Chronic hepatitis C virus (HCV) infection
Duavive (bazedoxifene / conjugated estrogens)	MR tablet 0.45 mg/20 mg	Oestrogen deficiency symptoms in postmenopausal women with a uterus
Esbriet (pirfenidone)	Capsule 267 mg	Idiopathic pulmonary fibrosis
Mirvaso (brimonidine)	Topical gel 3.3 mg/g	Rosacea
Opdivo (nivolumab)	Concentration for infusion 100 mg/10 mL and 40 mg/4 mL	Unresectable (Stage III) or metastatic (Stage IV) melanoma Advanced or metastatic squamous or non-squamous non-small cell lung cancer (NSCLC)
Simbrinza (brimonidine / brinzolamide)	Eye drops suspension 1%/0.2%	Open-angle glaucoma or ocular hypertension
Sunvepra (asunaprevir)	Capsule 100 mg	Chronic HCV infection
Visanne (dienogest)	Tablet 2 mg	Endometriosis
VPRIV (velaglucerase alpha)	Powder for infusion 400 units	Type I Gaucher disease

Abbreviations: FC film coated, MR modified release

A full description of each product can be found in individual medicine data sheets at www.medsafe.govt.nz/Medicines/infoSearch.asp